ESC Premium Access

Role of the gut microbiome for the cholesterol lowering effect of atorvastatin

Topic: Lipid Metabolism, Metabolic Syndrome, Diabetes

Congress Presentation

About the speaker

Miss Friederike Luise Zimmermann

Charite University Hospital, Berlin (Germany)
0 follower

4 more presentations in this session

State of the Art - Metabolic aspects of vascular disease

Speaker: Professor M. Federici (Rome, IT)


Identification of celastramycin as a novel therapeutic agent for pulmonary arterial hypertension -high-throughput screening of 5,562 compounds-

Speaker: Doctor R. Kurosawa (Sendai, JP)


The SGLT2 inhibitor empagliflozin reduces mortality in experimental pulmonary hypertension

Speaker: Professor S. Verma (Toronto, CA)


Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury

Speaker: Professor R. Touyz (Montreal, CA)


Access the full session

Novel pharmacological targets in vascular disease

Speakers: Miss F. Zimmermann, Professor M. Federici, Doctor R. Kurosawa, Professor S. Verma, Professor R. Touyz

About the event



31 August - 4 September 2019

Sessions Presentations

Related content

ESC Premium Access

Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt? – discussion.

29 August 2021

ESC Premium Access

Anti-inflammatory treatment of COVID-19 patients: which drugs and which patients?

29 August 2021

ESC Premium Access

COVID-19 myocarditis and myocardial injury: active participant or innocent bystander?

29 August 2021

ESC 365 is supported by

logo Novo Nordisk